JULIE ROMEIS: Open Payments
NPI 1033756598 · CARY, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$34,208 in 120 payments from 18 companies in 2025. Trend: 2023 $4,989 · 2024 $3,217 · 2025 $34,208
Speaker / faculty: $15,288Honoraria: $10,938Food & beverage: $3,290Consulting: $2,500Travel & lodging: $2,192
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 27 | $14,517 |
| Axsome Therapeutics, Inc. | 25 | $13,160 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $5,146 |
| Alkermes, Inc. | 17 | $228 |
| Vanda Pharmaceuticals Inc. | 4 | $207 |
| Neurocrine BioSciences, Inc. | 5 | $178 |
| ABBVIE INC. | 10 | $166 |
| Teva Pharmaceuticals USA, Inc. | 3 | $137 |
| E.R. Squibb & Sons, L.L.C. | 2 | $132 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $117 |
Products named: REXULTI, Auvelity, CAPLYTA, ARISTADA, INGREZZA, VRAYLAR, AUSTEDO XR, COBENFY.
Industry payments across NC — which companies pay providers there.
